Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/9945
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Dursunoğlu, Neşe. | - |
dc.contributor.author | Köktürk, N. | - |
dc.contributor.author | Baha, A. | - |
dc.contributor.author | Bilge, A.K. | - |
dc.contributor.author | Börekçi, Ş. | - |
dc.contributor.author | Çiftçi, F. | - |
dc.contributor.author | Karadağ, M.G. | - |
dc.date.accessioned | 2019-08-16T13:08:03Z | |
dc.date.available | 2019-08-16T13:08:03Z | |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0494-1373 | - |
dc.identifier.uri | https://hdl.handle.net/11499/9945 | - |
dc.identifier.uri | https://doi.org/10.5578/tt.2245 | - |
dc.description.abstract | Chronic obstructive pulmonary disease (COPD) is a complex disease that is associated with devastating outcomes resulting from lung involvement and several comorbidities. Comorbidities could impact on symptomology, quality of life, the complications, the management, economic burden and the mortality of the disease. The importance of comorbidities originates from their impact on the outcome of COPD. The most frequent comorbidities in COPD are cardiovascular, endocrinological, musculoskeletal, phycological disorders and lung cancer. Almost 50% of the COPD patients have 3 or more comorbidities. The recent Global Initiative of Obstructive Lung Disease (GOLD) Guideline suggested proactive search and the treatment of the comorbidities. However, there is no certain evidence demonstrating that active treatment of comorbidities improve the outcomes of COPD. However, it is well known that several comorbidities such as cardiovascular disease and lung cancer have greater impact on mortality caused by COPD. Several studies have shown that Charlson Comorbidity index or more recenty COPD Specific Comorbidity Index (COTE) has been found to be related with mortality of COPD. This concise review intended to summarize the most frequent comorbidities in association with their impact on COPD. © 2016, Ankara University. All rights reserved. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Ankara University | en_US |
dc.relation.ispartof | Tuberkuloz ve Toraks | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Comorbidity | en_US |
dc.subject | COPD | en_US |
dc.subject | C reactive protein | en_US |
dc.subject | calcium | en_US |
dc.subject | denosumab | en_US |
dc.subject | fibrinogen | en_US |
dc.subject | ghrelin | en_US |
dc.subject | growth hormone | en_US |
dc.subject | interleukin 1beta | en_US |
dc.subject | interleukin 6 | en_US |
dc.subject | megestrol | en_US |
dc.subject | parathyroid hormone[1-34] | en_US |
dc.subject | testosterone | en_US |
dc.subject | tumor necrosis factor | en_US |
dc.subject | vitamin D | en_US |
dc.subject | aging | en_US |
dc.subject | anemia | en_US |
dc.subject | anxiety | en_US |
dc.subject | Article | en_US |
dc.subject | asthma | en_US |
dc.subject | body mass | en_US |
dc.subject | chronic obstructive lung disease | en_US |
dc.subject | clinical trial (topic) | en_US |
dc.subject | comorbidity | en_US |
dc.subject | depression | en_US |
dc.subject | diabetes mellitus | en_US |
dc.subject | emphysema | en_US |
dc.subject | family history | en_US |
dc.subject | gastroesophageal reflux | en_US |
dc.subject | heart failure | en_US |
dc.subject | human | en_US |
dc.subject | hypertension | en_US |
dc.subject | ischemic heart disease | en_US |
dc.subject | lung cancer | en_US |
dc.subject | lung diffusion capacity | en_US |
dc.subject | lung fibrosis | en_US |
dc.subject | malnutrition | en_US |
dc.subject | metabolic syndrome X | en_US |
dc.subject | musculoskeletal disease | en_US |
dc.subject | obesity | en_US |
dc.subject | osteoporosis | en_US |
dc.subject | respiratory system | en_US |
dc.subject | sleep disorder | en_US |
dc.subject | smoking | en_US |
dc.subject | vitamin D deficiency | en_US |
dc.subject | Cardiovascular Diseases | en_US |
dc.subject | disease management | en_US |
dc.subject | health status | en_US |
dc.subject | Lung Neoplasms | en_US |
dc.subject | Musculoskeletal Diseases | en_US |
dc.subject | Pulmonary Disease, Chronic Obstructive | en_US |
dc.subject | quality of life | en_US |
dc.subject | cardiovascular disease | en_US |
dc.subject | complication | en_US |
dc.subject | lung tumor | en_US |
dc.subject | Diabetes Mellitus | en_US |
dc.subject | Disease Management | en_US |
dc.subject | Health Status | en_US |
dc.subject | Humans | en_US |
dc.subject | Quality of Life | en_US |
dc.title | Comorbidities and their impact on chronic obstructive pulmonary disease | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 64 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 289 | |
dc.identifier.startpage | 289 | en_US |
dc.identifier.endpage | 298 | en_US |
dc.authorid | 0000-0002-6323-3456 | - |
dc.identifier.doi | 10.5578/tt.2245 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.pmid | 28393718 | en_US |
dc.identifier.scopus | 2-s2.0-85012979807 | en_US |
dc.identifier.wos | WOS:000395279400005 | en_US |
dc.identifier.scopusquality | Q3 | - |
dc.owner | Pamukkale University | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
item.grantfulltext | open | - |
item.openairetype | Article | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
neşe dursunoğlu.pdf | 99.07 kB | Adobe PDF | View/Open |
CORE Recommender
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.